Cas 482615-39-4,Butanal, 2-[(triphenylmethyl)amino]-, (2S)-

482615-39-4

Post Buying Request

Basic information

Product Name: Butanal, 2-[(triphenylmethyl)amino]-, (2S)-
Synonyms:
CAS NO:482615-39-4
Molecular Formula: C23H23NO
Molecular Weight: 329.442
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: Butanal, 2-[(triphenylmethyl)amino]-, (2S)-(CAS DataBase Reference)
NIST Chemistry Reference: Butanal, 2-[(triphenylmethyl)amino]-, (2S)-(482615-39-4)
EPA Substance Registry System: Butanal, 2-[(triphenylmethyl)amino]-, (2S)-(482615-39-4)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 482615-39-4(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

482615-39-4 Suppliers

Recommended suppliers

482615-39-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 482615-39-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,8,2,6,1 and 5 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 482615-39:
(8*4)+(7*8)+(6*2)+(5*6)+(4*1)+(3*5)+(2*3)+(1*9)=164
164 % 10 = 4
So 482615-39-4 is a valid CAS Registry Number.

482615-39-4Upstream product

482615-39-4Downstream Products

482615-39-4Relevant academic research and scientific papers

Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors

Wilson, Stuart C.,Atrash, Butrus,Barlow, Clare,Eccles, Susan,Fischer, Peter M.,Hayes, Angela,Kelland, Lloyd,Jackson, Wayne,Jarman, Michael,Mirza, Amin,Moreno, Javier,Nutley, Bernard P.,Raynaud, Florence I.,Sheldrake, Peter,Walton, Mike,Westwood, Robert,Whittaker, Steven,Workman, Paul,McDonald, Edward

, p. 6949 - 6965 (2012/01/14)

The cyclin-dependent kinase (CDK) inhibitor seliciclib (1, CYC202) is in phase II clinical development for the treatment of cancer. Here we describe the synthesis of novel purines with greater solubility, lower metabolic clearance, and enhanced potency versus CDKs. These compounds exhibit novel selectivity profiles versus CDK isoforms. Compound αSβR-21 inhibits CDK2/cyclin E with IC50 = 30 nM, CDK7-cyclin H with IC50 = 1.3 μM, and CDK9-cyclinT with IC50 = 0.11 μM; it (CCT68127) inhibits growth of HCT116 colon cancer cells in vitro with GI50 = 0.7 μM; and shows antitumour activity when dosed p.o. at 50 mg/kg to mice bearing HCT116 solid human tumour xenografts.

COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS

-

, (2008/12/04)

The present invention relates to combination comprising (i) an ErbB inhibitor; and (ii) a CDK inhibitor, or a pharmaceutically acceptable salt thereof, selected from: (a) roscovitine; (b) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-

NEW PURINE DERIVATIVES

-

Page 38-39, (2008/06/13)

The present invention relates to compounds of formula (1) or pharmaceutically acceptable salts thereof, wherein one of R1 and R2 is methyl, ethyl or isopropyl, and the other is H; R3 and R4 are each independentl

NEW PURINE DERIVATIVES

-

Page 36-37, (2008/06/13)

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 482615-39-4